Chemotherapy options in castration-resistant prostate cancer

INTRODUCTION: The treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) is evolving, with recent approvals of immune therapy, novel hormonal therapy, and bone-targeted therapy. Chemotherapy remains an essential component of the armamentarium. Herein, we review...

Descripción completa

Detalles Bibliográficos
Autores principales: Teply, Benjamin A., Hauke, Ralph J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054655/
https://www.ncbi.nlm.nih.gov/pubmed/27843207
http://dx.doi.org/10.4103/0970-1591.191239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054655/
https://www.ncbi.nlm.nih.gov/pubmed/27843207
http://dx.doi.org/10.4103/0970-1591.191239

Ejemplares similares